Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Escherichia immuno modulatory receptor protective suppressive noncatalytic intra cellular nonlymphoid NF?B athero sclerosis auto immunity
- Product Overview:
Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic heme-containing enzyme involved in tryptophan catabolism that mediates multiple immunomodulatory processes.{50334,59708} It exists as a monomer and is composed of a large catalytic domain, which contains the heme group, and a small non-catalytic domain with two immunoreceptor tyrosine-based inhibition motifs (ITIMs) that regulate intracellular signaling.{59709,59710} IDO1 catalyzes the oxidation of L-tryptophan (Item No. 29600) to N-formylkynurenine, the first and rate-limiting step of the kynurenine pathway, leading to the production of several metabolites of kynurenine (Item No. 11305), including 3-hydroxy anthranilic acid (Item No. 20512), that have immunoprotective and immunosuppressive effects.{50334} IDO1 is widely expressed in several lymphoid and non-lymphoid organs, including lymph nodes, spleen, tonsils, lungs, and intestine, as well as immune cells, including macrophages and dendritic cells (DCs), and endothelial cells.{50334} IDO1 activity is regulated at the transcriptional level where expression of IDO1 is increased by the transcription factors NF-?B, aryl hydrocarbon receptor (AhR), and CCTF, which are induced by stimulation with toll-like receptor (TLR) ligands or cytokines and inhibited by hypoxia.{50334} IDO1 activity can also be inhibited at the protein level by peroxynitrite (Item No. 81565), leading to IDO1 inactivation, or suppressor of cytokine signaling 3 (SOCS3), which binds to and targets IDO1 for proteasomal degradation. Increased IDO1 activity is associated with numerous pathological conditions, including atherosclerosis, autoimmunity, HIV, and cancer. Cayman’s IDO1 (human, recombinant) protein can be used for enzyme assay applications. This protein consists of 402 amino acids and has a calculated molecular weight of 46 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.